PR Newswire BiotechOriginal article
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
Phase 2positiveASC50Positive
AI Analysis
Summary
Ascletis announced positive Phase 2 proof-of-concept results for ASC50, its first-in-class and best-in-class oral IL-17A inhibitor, demonstrating 48.9% placebo-adjusted PASI score reduction in mild-to-moderate plaque psoriasis patients with once-daily 200 mg dosing.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
48.9% placebo-adjusted reduction in PASI score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg treatment over 28 days
Importance:6/10
Sentiment:
0.85
IL-17A inhibitororal small moleculefirst-in-classbest-in-classplaque psoriasisproof-of-conceptdermatology
Read the original article
Published by PR Newswire Biotech on September 29, 2026 12:00 AM